Skip to main
HRMY
HRMY logo

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is positioned for significant growth due to its strong commercial performance from WAKIX and an advancing pipeline of drug candidates, which are expected to initiate or report results from multiple registrational trials in the next 12 to 18 months. The company maintains a robust balance sheet that supports its internal research and development efforts as well as potential business development opportunities. Despite the setback of ZYN002 not meeting its primary endpoint, the consistent execution in business operations and the potential of its pipeline contribute to a positive outlook for the company's future growth in the neurology sector.

Bears say

The analysis of Harmony Biosciences Holdings Inc indicates a significant setback due to the inability of its drug candidate ZYN002 to meet the primary endpoint in the pivotal Phase 3 RECONNECT trial, primarily attributed to a higher-than-expected placebo response. This revelation raises concerns regarding the efficacy of their pipeline and the capability to deliver therapeutic benefits in a critical patient population with unmet medical needs. Furthermore, the challenges faced in this trial may impact investor confidence and future revenue expectations, thereby contributing to a negative outlook on the company's stock performance.

HRMY has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Strong Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.